Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line

Research output: Contribution to journalArticle

Abstract

Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary culture of MFS (IM-MFS-1) and compared the cell morphology with patient's tumor tissue. IM-MFS-1 was genetically characterized through a Comparative Genomic Hybridization (CGH) array and the mesenchymal phenotype was evaluated using Polymerase chain reaction (PCR) and immunofluorescence staining. Drug sensitivity for MFS therapies was monitored over time in cultures. We confirmed the conservation of the patient's tumor cell morphology and of the mesenchymal phenotype. Conversely, the synthesis and expression of CD109, a TGFβ co-receptor used to facilitate the diagnosis of high-grade MFS diagnosis, was maintained constant until high cancer cell line passages. The CGH array revealed a complex karyotype with cytogenetic alterations that include chromosome regions associated with genes involved in tumor processes. Cytotoxicity assays show drug sensitivity constantly increased during the culture passages until a plateau was reached. In conclusion, we established and characterized a new MFS cell line that can be used for future preclinical and molecular studies on soft tissue sarcomas.

Original languageEnglish
JournalCells
Volume7
Issue number11
DOIs
Publication statusPublished - Oct 25 2018

Fingerprint

Tumors
Cells
Cell Line
Pharmaceutical Preparations
Neoplasms
Comparative Genomic Hybridization
Tissue
Sarcoma
Polymerase chain reaction
Cytotoxicity
Chromosomes
Phenotype
Assays
Conservation
Genes
Availability
Karyotype
Cytogenetics
Fluorescent Antibody Technique
Staining and Labeling

Cite this

@article{903d9ea27c3d4a7998bd0a383be9a220,
title = "Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line",
abstract = "Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1{\%} of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary culture of MFS (IM-MFS-1) and compared the cell morphology with patient's tumor tissue. IM-MFS-1 was genetically characterized through a Comparative Genomic Hybridization (CGH) array and the mesenchymal phenotype was evaluated using Polymerase chain reaction (PCR) and immunofluorescence staining. Drug sensitivity for MFS therapies was monitored over time in cultures. We confirmed the conservation of the patient's tumor cell morphology and of the mesenchymal phenotype. Conversely, the synthesis and expression of CD109, a TGFβ co-receptor used to facilitate the diagnosis of high-grade MFS diagnosis, was maintained constant until high cancer cell line passages. The CGH array revealed a complex karyotype with cytogenetic alterations that include chromosome regions associated with genes involved in tumor processes. Cytotoxicity assays show drug sensitivity constantly increased during the culture passages until a plateau was reached. In conclusion, we established and characterized a new MFS cell line that can be used for future preclinical and molecular studies on soft tissue sarcomas.",
author = "Giacomo Miserocchi and {De Vita}, Alessandro and Laura Mercatali and Federica Recine and Chiara Liverani and Chiara Spadazzi and Federica Pieri and Nada Riva and Alberto Bongiovanni and Roberto Casadei and Valentina Fausti and Toni Ibrahim",
year = "2018",
month = "10",
day = "25",
doi = "10.3390/cells7110186",
language = "English",
volume = "7",
journal = "Cells",
issn = "2073-4409",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line

AU - Miserocchi, Giacomo

AU - De Vita, Alessandro

AU - Mercatali, Laura

AU - Recine, Federica

AU - Liverani, Chiara

AU - Spadazzi, Chiara

AU - Pieri, Federica

AU - Riva, Nada

AU - Bongiovanni, Alberto

AU - Casadei, Roberto

AU - Fausti, Valentina

AU - Ibrahim, Toni

PY - 2018/10/25

Y1 - 2018/10/25

N2 - Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary culture of MFS (IM-MFS-1) and compared the cell morphology with patient's tumor tissue. IM-MFS-1 was genetically characterized through a Comparative Genomic Hybridization (CGH) array and the mesenchymal phenotype was evaluated using Polymerase chain reaction (PCR) and immunofluorescence staining. Drug sensitivity for MFS therapies was monitored over time in cultures. We confirmed the conservation of the patient's tumor cell morphology and of the mesenchymal phenotype. Conversely, the synthesis and expression of CD109, a TGFβ co-receptor used to facilitate the diagnosis of high-grade MFS diagnosis, was maintained constant until high cancer cell line passages. The CGH array revealed a complex karyotype with cytogenetic alterations that include chromosome regions associated with genes involved in tumor processes. Cytotoxicity assays show drug sensitivity constantly increased during the culture passages until a plateau was reached. In conclusion, we established and characterized a new MFS cell line that can be used for future preclinical and molecular studies on soft tissue sarcomas.

AB - Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totality of adult tumors worldwide. Thus, given the rare nature of this cancer, this makes the availability of MFS cell lines difficult. In an attempt to partially fill this gap, we immortalized a primary culture of MFS (IM-MFS-1) and compared the cell morphology with patient's tumor tissue. IM-MFS-1 was genetically characterized through a Comparative Genomic Hybridization (CGH) array and the mesenchymal phenotype was evaluated using Polymerase chain reaction (PCR) and immunofluorescence staining. Drug sensitivity for MFS therapies was monitored over time in cultures. We confirmed the conservation of the patient's tumor cell morphology and of the mesenchymal phenotype. Conversely, the synthesis and expression of CD109, a TGFβ co-receptor used to facilitate the diagnosis of high-grade MFS diagnosis, was maintained constant until high cancer cell line passages. The CGH array revealed a complex karyotype with cytogenetic alterations that include chromosome regions associated with genes involved in tumor processes. Cytotoxicity assays show drug sensitivity constantly increased during the culture passages until a plateau was reached. In conclusion, we established and characterized a new MFS cell line that can be used for future preclinical and molecular studies on soft tissue sarcomas.

U2 - 10.3390/cells7110186

DO - 10.3390/cells7110186

M3 - Article

C2 - 30366467

VL - 7

JO - Cells

JF - Cells

SN - 2073-4409

IS - 11

ER -